Annual Results Results Snapshot
Figures in Cr
Consolidate Annual Results
Mar'25
Mar'24
Net Sales
502.00
459.28
Other Operating Income
0.00
0.00
Total Operating income
502.00
459.28
Raw Material Cost
208.63
153.74
Purchase of Finished goods
0.00
0.00
(Increase) / Decrease In Stocks
-43.84
11.57
Employee Cost
38.34
29.41
Power Cost
0.00
0.00
Manufacturing Expenses
0.00
0.00
Selling and Distribution Expenses
0.00
0.00
Other Expenses
108.92
82.91
Total Expenditure (Excl Depreciation)
312.05
277.63
Operating Profit (PBDIT) excl Other Income
189.95
181.65
Other Income
9.33
6.10
Operating Profit (PBDIT)
199.28
187.75
Interest
5.85
3.92
Exceptional Items
0.00
0.00
Gross Profit (PBDT)
193.43
183.83
Depreciation
10.59
9.01
Profit Before Tax
182.85
174.82
Tax
44.12
41.63
Provisions and contingencies
0.00
0.00
Profit After Tax
138.73
133.19
Extraordinary Items
0.00
0.00
Prior Period Expenses
0.00
0.00
Other Adjustments
0.00
0.00
Net Profit
138.73
133.19
Share in Profit of Associates
0.00
0.00
Minority Interest
0.00
0.00
Other related items
0.00
0.00
Consolidated Net Profit
138.73
133.19
Equity Capital
9.72
1.41
Face Value
1.0
1.0
Reserves
481.12
354.63
Earnings per share (EPS)
14.27
1.59
Diluted Earnings per share
12.79
1.59
Operating Profit Margin (Excl OI)
37.84%
39.55%
Gross Profit Margin
38.53%
40.03%
PAT Margin
27.64%
29.0%
Public Share Holdings (%)
0.0%
0.0%
Pledged Promotor Holding (%)
0.0%
0.0%
Annual Analysis Highlights
Analysis not available as Data has been published for only 1 period
Compare Annual Results Of Sudeep Pharma With
Figures in Cr
Consolidate Annual Results
Change(INR)
Change(%)
Net Sales
502.00
4,118.16
-3,616.16
-87.81%
Other Operating Income
0.00
0.00
0.00
Total Operating income
502.00
4,118.16
-3,616.16
-87.81%
Raw Material Cost
208.63
2,253.61
-2,044.98
-90.74%
Purchase of Finished goods
0.00
181.47
-181.47
-100.00%
(Increase) / Decrease In Stocks
-43.84
-1.65
-42.19
-2,556.97%
Employee Cost
38.34
715.82
-677.48
-94.64%
Power Cost
0.00
0.00
0.00
Manufacturing Expenses
0.00
-3.86
3.86
100.00%
Selling and Distribution Expenses
0.00
0.00
0.00
Other Expenses
108.92
508.28
-399.36
-78.57%
Total Expenditure (Excl Depreciation)
312.05
3,653.67
-3,341.62
-91.46%
Operating Profit (PBDIT) excl Other Income
189.95
464.49
-274.54
-59.11%
Other Income
9.33
52.12
-42.79
-82.10%
Operating Profit (PBDIT)
199.28
516.61
-317.33
-61.43%
Interest
5.85
34.60
-28.75
-83.09%
Exceptional Items
0.00
16.70
-16.70
-100.00%
Gross Profit (PBDT)
193.43
498.71
-305.28
-61.21%
Depreciation
10.59
153.45
-142.86
-93.10%
Profit Before Tax
182.85
345.25
-162.40
-47.04%
Tax
44.12
1.48
42.64
2,881.08%
Provisions and contingencies
0.00
0.00
0.00
Profit After Tax
138.73
343.78
-205.05
-59.65%
Extraordinary Items
0.00
0.00
0.00
Prior Period Expenses
0.00
0.00
0.00
Other Adjustments
0.00
0.00
0.00
Net Profit
138.73
343.78
-205.05
-59.65%
Share in Profit of Associates
0.00
0.00
0.00
Minority Interest
0.00
-5.60
5.60
100.00%
Other related items
0.00
0.00
0.00
Consolidated Net Profit
138.73
338.18
-199.45
-58.98%
Equity Capital
9.72
30.62
-20.90
-68.26%
Face Value
1.00
2.00
0.00
Reserves
481.12
3,016.39
-2,535.27
-84.05%
Earnings per share (EPS)
14.27
22.09
-7.82
-35.40%
Diluted Earnings per share
12.79
22.60
-9.81
-43.41%
Operating Profit Margin (Excl OI)
37.84%
11.28%
0.00
26.56%
Gross Profit Margin
38.53%
12.11%
0.00
26.42%
PAT Margin
27.64%
8.35%
0.00
19.29%
Public Share Holdings (%)
0.00%
0.00%
0.00
0.00%
Pledged Promotor Holding (%)
0.00%
0.00%
0.00
0.00%
Annual - Net Sales
Net Sales 356.73 Cr
in Mar 2025Figures in Cr
Annual - Standalone Net Profit
Standalone Net Profit 95.75 Cr
in Mar 2025Figures in Cr
Annual - Operating Profit (PBDIT)
Operating Profit (PBDIT) 131.96 Cr
in Mar 2025Figures in Cr
Annual - Interest
Interest 4.81 Cr
in Mar 2025Figures in Cr
Annual - Operating Profit Margin (Excl OI)
Operating Profit Margin (Excl OI) 36.99%
in Mar 2025Figures in %
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
